VACCINEX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.1 USD | -3.48% |
|
-11.01% | -34.46% |
| Sales 2022 | 3L 2.3Cr | Sales 2023 | 6L 4.76Cr | Capitalization | 83.06L 69Cr |
|---|---|---|---|---|---|
| Net income 2022 | -1.9Cr -158.72Cr | Net income 2023 | -2Cr -167.07Cr | EV / Sales 2022 | 95.4 x |
| Net cash position 2022 | 59.06L 49Cr | Net cash position 2023 | 12.88L 11Cr | EV / Sales 2023 | 12.3 x |
| P/E ratio 2022 |
-1.37
x | P/E ratio 2023 |
-0.21
x | Employees | 39 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.48% | ||
| 1 week | -11.01% | ||
| Current month | -10.03% | ||
| 1 month | +9.14% | ||
| 3 months | -22.49% | ||
| 6 months | -37.94% | ||
| Current year | -34.46% |
1 week
5.99
7.03
1 month
4.808.22
Current year
4.4313.02
1 year
4.4383.56
3 years
4.43617.40
5 years
4.432 568.30
10 years
4.432 568.30
| Managers | Title | Age | Since |
|---|---|---|---|
Maurice Zauderer
FOU | Founder | 78 | 01/97/01 |
Elizabeth Evans
COO | Chief Operating Officer | 52 | 01/01/01 |
Ernie Smith
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/01/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bala S. Manian
BRD | Director/Board Member | 77 | 01/04/01 |
Albert Friedberg
CHM | Chairman | 77 | 01/97/01 |
Chrystyna Stecyk
BRD | Director/Board Member | 61 | 14/20/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 6.1 | -3.48% | 24,280 |
| 20/24/20 | 6.32 | +3.10% | 5,247 |
| 18/24/18 | 6.13 | -5.84% | 16,141 |
| 17/24/17 | 6.51 | -5.03% | 7,541 |
| 14/24/14 | 6.855 | -4.79% | 25,979 |
Delayed Quote Nasdaq, June 22, 2024 at 01:30 am IST
More quotes
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâs disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -34.46% | 96.64L | |
| +15.19% | 12TCr | |
| +19.91% | 11TCr | |
| -19.80% | 2.04TCr | |
| -16.19% | 1.65TCr | |
| -13.45% | 1.64TCr | |
| -44.35% | 1.56TCr | |
| +66.67% | 1.52TCr | |
| +2.13% | 1.35TCr | |
| +119.39% | 1.1TCr |
- Stock Market
- Equities
- VCNX Stock
